ONC 8-K Current Reports

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 26, 2026)

BeOne Medicines Ltd. (ONC) furnished this Form 8-K to disclose that it filed its 2026 Interim Report for the six months ended June 30, 2026 with the Shanghai Stock Exchange STAR Market. The filing is primarily a regulatory disclosure under PRC rules, and it provides supplementary R&D expense data by product and project, prepared under U.S. GAAP. The Item 2.02 disclosure is furnished, not filed, and the STAR Interim Report itself is available only in Chinese on the SSE website. No headline revenue, net income, or guidance figures appear in the excerpt, so investors should treat it as a supplemental disclosure rather than a full earnings release. The most quantitatively important data is R&D spending. Total R&D expense (U.S. GAAP) for the six months ended June 30, 2026 was $1,153.5 million, up about 14.6% from $1,006.8 million a year earlier. Internal R&D rose to $718.4 million from $606.5 million, while external R&D (including collaborations) rose to $435.1 million from $400.3 million. Among key programs, BEQALZI (sonrotoclax) fell to $74.0 million from $94.0 million, and BRUKINSA fell to $42.7 million from $63.0 million, while newer programs such as BGB-43395 (CDK4), BGB-B2033, BG-C9074, BGB-58067 and BG-C477 more than tripled or grew sharply from small bases. Tacabrutideg (BTK-targeted CDAC) rose to $44.3 million from $26.9 million, signaling a shift in spending toward pipeline expansion. The filing also flags accounting differences between PRC GAAP and U.S. GAAP. These cover share-based compensation attribution, interim tax rate methodology, lease expense presentation, and, most notably, the treatment of the 2025 sale of future royalty rights. Under U.S. GAAP the upfront proceeds are a liability with an effective-interest expense, while under PRC GAAP they are deferred revenue amortized over the collaboration period. These differences mean reported profit can differ materially between the two frameworks in any given period, so investors comparing STAR and SEC figures should reconcile them carefully.

Aug 26, 2026 8-K

Leadership ChangesShareholder MattersExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 5, 2026)

BeOne Medicines (NASDAQ: ONC) reported strong second-quarter 2026 results, with total revenue of $1.705 billion, up 30% year over year, driven primarily by BRUKINSA (global sales of $1.2 billion, up 31%; U.S. sales of $893 million, up 31%). Product gross margin expanded to 90% from 87%, reflecting higher BRUKINSA mix and productivity gains. GAAP operating income rose to $325 million from $88 million, and GAAP net income reached $237 million (diluted EPS of $2.05 per ADS) versus $94 million a year earlier. Free cash flow was $435 million, up 98%, and cash, cash equivalents and restricted cash rose to $5.28 billion at June 30, 2026. Operating expenses grew 13% on a GAAP basis, but SG&A fell to 35% of product sales from 41%, indicating operating leverage. Management raised full-year 2026 guidance: total revenue to $6.6-6.8 billion (from $6.3-6.5 billion), GAAP operating income to $1.0-1.1 billion (from $750-850 million), and non-GAAP operating income to $1.7-1.8 billion (from $1.45-1.55 billion). The company also flagged a possible material income tax benefit from reversing valuation allowances in 2026, though timing and magnitude are uncertain. This tax item could meaningfully boost reported GAAP net income and EPS in a future period, so investors should separate it from operating performance. Key near-term catalysts include 2H 2026 regulatory submissions for BRUKINSA in first-line mantle cell lymphoma, FDA action on TEVIMBRA plus ZIIHERA in first-line HER2-positive gastroesophageal adenocarcinoma, and several pipeline milestones. Note that the 2Q GAAP results include a $49.8 million discrete tax benefit, and that non-GAAP figures exclude share-based compensation and depreciation. Leverage also rose: debt increased to $1.07 billion and interest expense reached $40 million in the quarter, and the Royalty Pharma arrangement continues to affect other expense. The press release figures are unaudited.

Aug 5, 2026 8-K

Other Events

BeOne Medicines Ltd. 8-K Report, Corporate Update (Jun 26, 2026)

BeOne Medicines Ltd. (ONC) disclosed under Item 8.01 that it concluded a statutory tax audit in China and reached a settlement with the local tax authority. The settlement requires the company to adjust previously filed tax returns, resulting in an income tax payment of approximately RMB 446 million, including surcharges and related interest. The settlement involved no administrative penalty. The company expects to recognize the payment in its U.S. GAAP financial statements for the second quarter of fiscal 2026. The filing does not state the payment's impact on earnings, cash flow, or guidance, and it does not say whether the amount was previously reserved. Investors will likely need to review the company's second-quarter results and related disclosures to assess the effect on reported earnings and liquidity. The filing references the company's May 6, 2026 Form 10-Q, which already warned that ongoing tax audits in non-U.S. jurisdictions could produce liabilities materially different from current estimates. This settlement is a concrete example of that risk, which suggests the company's exposure to cross-border tax complexity is an ongoing theme for investors to monitor.

Jun 26, 2026 8-K

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jun 11, 2026)

BeOne Medicines Ltd. (ONC) held its Annual General Meeting on June 11, 2026, where key corporate governance and compensation matters were addressed. Notably, four directors, Michael Goller, Ranjeev Krishana, Dr. Corazon (Corsee) D. Sanders, and Qingqing Yi, did not seek re-election, and their terms concluded without disagreement. Shareholders overwhelmingly approved amendments to the Company's 2016 Share Option and Incentive Plan and the 2018 Employee Share Purchase Plan, significantly increasing the number of shares available for issuance under both. The company also received shareholder approval for its 2025 financial statements and the appropriation of accumulated losses. Significant votes of confidence were also cast for the re-election of existing directors and the election of new board members, including a new Compensation Committee member and the re-election of the Chairman of the Board. The appointment of Ernst & Young LLP as independent auditors for fiscal year 2026 was ratified.

Jun 11, 2026 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (May 15, 2026)

BeOne Medicines Ltd. (Nasdaq: ONC) disclosed in an 8-K filed May 15, 2026, that the U.S. FDA granted accelerated approval to BEQALZI (sonrotoclax), a next-generation BCL2 inhibitor, for adult patients with relapsed or refractory mantle cell lymphoma (R/R MCL) who have received at least two lines of systemic therapy, including a BTK inhibitor. The approval, announced May 13, 2026, is the first new BCL2 inhibitor approved in the U.S. in roughly a decade and the only BCL2 inhibitor approved for MCL. The filing itself is a brief Item 8.01 (Other Events) report that incorporates the press release as Exhibit 99.1, so the substantive information is in that release rather than in the 8-K's financial disclosures. The approval rests on the Phase 1/2 study BGB-11417-201, presented at ASH, which showed an overall response rate of 52% (95% CI, 42-62), a complete response rate of 16%, and a median duration of response of 15.8 months, though follow-up is still immature (median 11.9 months). Because the approval is accelerated, continued approval depends on confirmatory benefit being shown in the ongoing CELESTIAL-RRMCL trial. The label carries a boxed-style set of warnings for tumor lysis syndrome (7% laboratory or clinical TLS), serious infections (14%, with 2.6% fatal), and neutropenia (Grade 3-4 in 18%), along with embryo-fetal toxicity risk. For investors, the approval expands BeOne's hematology franchise and adds a differentiated mechanism in a market with limited options after BTK inhibitor failure. The filing does not disclose commercial launch timing, pricing, sales expectations, or revenue impact, so investors should look to subsequent company disclosures for those variables. The release also notes that BEQALZI is approved in China for R/R MCL and CLL/SLL, is under review by the European Medicines Agency, and is being studied in combination with zanubrutinib in CLL.

May 15, 2026 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (May 6, 2026)

BeOne Medicines (NASDAQ: ONC) reported first-quarter 2026 results that showed strong top-line momentum and a sharp improvement in profitability. Total revenue rose 35% year over year to $1.51 billion, led by foundational BRUKINSA (zanubrutinib), with global BRUKINSA sales of $1.1 billion (up 38%) and U.S. BRUKINSA sales of $761 million (up 35%). GAAP income from operations swung to $250 million from $11 million a year earlier, GAAP net income reached $227 million versus $1 million, and free cash flow was $161 million versus a $12 million outflow. Gross margin on product sales expanded to 89% from 85%, and SG&A fell to 37% of product sales from 41%, pointing to meaningful operating leverage. The company raised its full-year 2026 guidance for total revenue to $6.3–$6.5 billion (from $6.2–$6.4 billion) and for GAAP operating income to $750–$850 million (from $700–$800 million). Non-GAAP operating income guidance was raised to $1.45–$1.55 billion. Management also flagged a possible material income tax benefit later in 2026 if valuation allowances on deferred tax assets are reversed, though the timing and size are uncertain. Investors should note that operating expenses are growing faster than revenue in percentage terms, that the company carries $1.08 billion of debt and a $904 million sale-of-future-royalty liability, and that the press release's non-GAAP metrics exclude share-based compensation of $123 million in the quarter. On the pipeline side, management highlighted the fixed-duration sonrotoclax plus BRUKINSA combination as a potential first-line CLL standard of care, and BGB-16673 (BTK CDAC) as a potential first-in-class option in relapsed or refractory disease. Near-term catalysts include an FDA decision on sonrotoclax in R/R MCL in 1H 2026, a Phase 3 MANGROVE interim analysis in first-line MCL in 1H 2026, and an FDA decision on TEVIMBRA plus ZIIHERA in first-line HER2-positive gastroesophageal adenocarcinoma in 2H 2026, following Priority Review acceptance.

May 6, 2026 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Apr 14, 2026)

BeOne Medicines (ONC) furnished this 8-K under Item 2.02 to disclose supplemental financial information from its 2025 Annual Report, filed April 14, 2026 with the Shanghai Stock Exchange STAR Market under PRC rules. The filing itself is not a traditional earnings release. It contains no new guidance, no commentary on drivers, and no full financial statements. Its substance is in Exhibit 99.1, which presents U.S. GAAP-basis regional gross margin, R&D allocated by program, and production/sales/inventory data, plus a qualitative summary of differences between U.S. GAAP and PRC GAAP. The disclosed numbers show strong 2025 top-line growth. Total revenue was about $5.34 billion, up roughly 40% from $3.81 billion in 2024. Ex-China revenue grew about 53% to $3.66 billion, while China grew about 19% to $1.68 billion. Blended gross margin rose from roughly 84% to roughly 87%, driven mainly by China gross margin improving from 62.9% to 66.6%. Ex-China margin was essentially flat at about 97%. Ex-China cost of goods rose about 55%, a faster rate than the revenue-based margin gain would suggest, so mix and scale effects are worth monitoring. R&D spending rose about 10% to $2.15 billion. Mix shifted toward newer assets: sonrotoclax R&D increased about 77% to $177 million, and BGB-16673 rose more than fourfold to $94 million, while BRUKINSA and TEVIMBRA R&D declined. External R&D grew about 18%, while internal R&D grew about 5%. R&D collaboration project spending fell about 45%. Investors should note that the filing does not explain the drivers of these changes, and that the Chinese-language STAR report, not this exhibit, is the primary source for the PRC-basis figures.

Apr 14, 2026 8-K

Material AgreementsFinancial Events

BeOne Medicines Ltd. 8-K Report, Financial Results (Feb 26, 2026)

BeOne Medicines (ONC) reported strong fourth quarter and full-year 2025 results, with total revenue of $1.50 billion in Q4 (up 33% year over year) and $5.34 billion for the full year (up 40%). Growth was driven overwhelmingly by BRUKINSA (zanubrutinib), which generated $1.1 billion globally in Q4 and $3.9 billion for the year (up 38% and 49%, respectively). U.S. BRUKINSA sales reached $2.8 billion for the full year. Profitability improved sharply: GAAP operating income swung to $447 million for 2025 from a $568 million loss in 2024, GAAP net income was $287 million versus a $645 million loss, and free cash flow reached $942 million. Gross margin on a GAAP basis expanded to 87.3% for the year, reflecting product mix and operating leverage. management guided to 2026 total revenue of $6.2 to $6.4 billion, a GAAP gross margin in the high-80% range, GAAP operating income of $700 to $800 million, and non-GAAP operating income of $1.4 to $1.5 billion. Notably, management flagged that earnings may support a reversal of certain deferred tax valuation allowances in 2026, which could produce a material one-time tax benefit, though timing and size are uncertain. Other income/expense is expected to be a $25 to $50 million expense, and diluted ADS outstanding is projected at about 118 million. The pipeline update centers on near-term regulatory and data catalysts, including FDA action on sonrotoclax for relapsed/refractory mantle cell lymphoma (priority review granted), a Phase 3 MANGROVE interim analysis in first-line MCL in 1H 2026, and planned TEVIMBRA sBLA submissions for first-line HER2-positive gastroesophageal adenocarcinoma. Investors should note that the results were disclosed via an Item 2.02 furnishing (Exhibit 99.1), and that the quarter included about $76 million of full-year equity investment impairments and $45 million of tax items, which weighed on GAAP net income.

Feb 26, 2026 8-K

Material Agreements

BeOne Medicines Ltd. 8-K Report, Agreement Terminated (Dec 19, 2025)

BeOne Medicines Ltd. (ONC) has announced the termination of its credit facility with China Merchants Bank Co., Ltd. (CMB Credit Facility), effective December 16, 2025. This termination was facilitated by the full repayment of outstanding amounts using proceeds from a new Facilities Agreement, previously disclosed on November 19, 2025. The company also terminated all future credit commitments and associated guarantees and security interests under the CMB Credit Facility. Importantly, no termination penalties were incurred as a result of this action. This move indicates a financial restructuring for BeOne Medicines, potentially reflecting a shift in its financing strategy or a desire to consolidate debt under a new agreement. The absence of penalties suggests a smooth transition and a favorable outcome for the company. Investors should monitor how this new Facilities Agreement impacts the company's liquidity, debt levels, and overall financial flexibility moving forward.

Dec 19, 2025 8-K

Leadership Changes

BeOne Medicines Ltd. 8-K Report, Executive Changes (Dec 18, 2025)

BeOne Medicines Ltd. (ONC) has announced a significant leadership change, promoting Dr. Lai Wang to President, Global Head of Research and Development, effective January 1, 2026. This appointment underscores the company's commitment to advancing its R&D pipeline and strategic growth. Dr. Wang's extensive tenure with the company since 2011, coupled with his prior experience, makes him a well-qualified candidate to lead these critical functions. Investors should note the new compensation package, which includes a substantial base salary, performance-based bonus potential, and a significant equity award, reflecting the importance of his role in driving future value. The promotion of Dr. Wang to a broader leadership role, encompassing business development and alliance management alongside R&D, signals a strategic alignment of these key functions. This integration is expected to streamline decision-making and accelerate the progression of BeOne Medicines' drug candidates through development and potential partnerships. The company's decision to incentivize Dr. Wang with a considerable equity award highlights management's confidence in his ability to deliver long-term shareholder value.

Dec 18, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Material Agreement (Nov 19, 2025)

BeOne Medicines Ltd. (ONC) has announced the execution of a significant Facilities Agreement, securing senior secured financing totaling approximately $990 million. This facility includes a $140 million B1 Revolving Loan Facility and a $560 million B2 Term Loan Facility, both denominated in U.S. dollars, along with a $300 million A Term Loan Facility denominated in Renminbi. The funds are earmarked for general corporate purposes, including working capital, refinancing existing offshore debt, and associated fees. This substantial debt financing provides BeOne Medicines with considerable financial flexibility to support its ongoing operations and strategic initiatives. The agreement also outlines specific terms regarding loan utilization, maturity dates (36 months for the A Loan, 24 months for B Loans), interest rates (RMB Reference Rate + 0.65% for A Loan, USD Reference Rate + 2.40% for B Loans), and repayment schedules. The loan facilities are secured by equity interests in a subsidiary and the Company's New Jersey manufacturing and R&D facility, with guarantees from certain subsidiaries. The agreement includes customary covenants and events of default, as well as provisions for voluntary prepayments and mandatory prepayments under certain circumstances like a change of control.

Nov 19, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 6, 2025)

BeOne Medicines (ONC) reported strong third quarter 2025 results, with total revenue rising 41% year over year to $1.41 billion and product revenue reaching $1.40 billion. Growth was driven primarily by BRUKINSA (zanubrutinib), whose global sales rose 51% to roughly $1.0 billion, with U.S. BRUKINSA sales of $739 million (+47%) and European sales of $163 million (+68%). TEVIMBRA (tislelizumab) sales grew 17% to $191 million. Profitability improved sharply: GAAP net income was $124.8 million (diluted EPS of $1.09 per ADS) versus a $121.4 million loss a year earlier, and non-GAAP diluted EPS was $2.65 per ADS. Gross margin expanded to 85.9% on a GAAP basis, and free cash flow was $354 million, compared with $55 million in the prior-year quarter. Management raised its full-year 2025 total revenue guidance to $5.1–$5.3 billion from $5.0–$5.3 billion, primarily by lifting the low end. GAAP operating expense guidance was narrowed to $4.1–$4.3 billion from $4.1–$4.4 billion. Gross margin, operating income, and free cash flow guidance were left unchanged. Cash, cash equivalents and restricted cash rose to $4.1 billion at quarter-end, partly reflecting an $885 million royalty financing liability tied to a Royalty Pharma agreement covering Amgen's IMDELLTRA sales outside China, worth up to $950 million. The pipeline update points to several near-term catalysts, including a BGB-16673 (BTK degrader) data readout for a potential accelerated approval submission in CLL in 1H 2026, a Phase 3 head-to-head trial versus pirtobrutinib, and sonrotoclax Phase 3 enrollment starting in 1H 2026. Zanidatamab Phase 3 PFS data are expected in 2H 2025. Investors should note that the quarter benefited from lower in-process R&D upfront and milestone payments, and that GAAP figures still include substantial share-based compensation. Non-GAAP metrics exclude these items, so the gap between GAAP and adjusted results remains large.

Nov 6, 2025 8-K

Material AgreementsFinancial EventsRegulation FD+1

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 29, 2025)

On August 29, 2025, BeOne Medicines Ltd. (formerly BeiGene) filed an 8-K furnishing supplemental financial information from its 2025 Interim Report for the six months ended June 30, 2025, which was filed with the Shanghai Stock Exchange STAR Market under PRC rules. The filing does not contain new headline U.S. GAAP results or guidance. Its main content is an R&D expense breakdown by product and project, prepared under U.S. GAAP, plus a summary of differences between PRC GAAP and U.S. GAAP. The PRC report itself is available only in Chinese, and the 8-K states it is furnished, not filed, so it is not subject to Section 18 liabilities. The R&D disclosure shows total R&D expense of about $1.007 billion for the first half of 2025, up from $915 million in the prior-year period, a rise of roughly 10%. Internal R&D rose modestly to $607 million from $585 million. External R&D rose to $400 million from $330 million, driven mainly by the BCL2 program (BGB-11417), which increased from $39 million to $94 million, and the CDAC (BGB-16673) and CDK4 (BGB-43395) programs, which increased sharply from small bases. Tislelizumab and other R&D projects also grew, while R&D collaboration projects fell from $82 million to $48 million. Zanubrutinib spending was essentially flat. Investors should read this filing as a supplemental disclosure rather than an earnings release. Its value lies in showing where R&D dollars are going, with the BCL2, CDAC, and CDK4 programs carrying the most growth. The accounting differences noted, including share-based compensation, interim tax rate methodology, and lease accounting, affect reported profit timing under PRC GAAP but not the U.S. GAAP figures presented here. Readers should refer to the company's U.S. GAAP 10-Q for complete financial results.

Aug 29, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Material Agreement (Aug 25, 2025)

On August 25, 2025, BeOne Medicines Ltd. (Nasdaq: ONC) entered into a Royalty Purchase Agreement with Royalty Pharma under which BeOne's Seller subsidiary sold a significant portion of its rights to tiered mid-single-digit royalties on ex-China net revenue from IMDELLTRA (tarlatamab), a Amgen-developed DLL3-targeting bispecific T-cell engager. BeOne receives an upfront payment of $885 million at closing, with an option to sell an additional portion of royalties for up to $65 million exercisable through August 25, 2026, for a total potential value of up to $950 million. BeOne continues to share in royalties on annual Imdelltra ex-China net revenue above $1.5 billion and retains its other economic interests under the Amgen Collaboration Agreement. The transaction is structured to route royalty payments from Amgen into an escrow account, and BeOne has agreed to covenants restricting how it exercises its rights under the Amgen Collaboration Agreement, including its right to amend, assign, or terminate that agreement. The company expects the upfront payment to be a material direct financial obligation at closing, which it disclosed under Item 2.03. The royalty stream is effectively monetized in exchange for near-term cash, so the deal trades future royalty income for immediate liquidity. For investors, the agreement meaningfully strengthens BeOne's balance sheet and gives it operational and strategic flexibility, as management emphasized. The main trade-offs are the loss of a portion of future Imdelltra royalty upside, which is most valuable at higher sales levels, and the restrictions on Amgen collaboration decisions. The full agreement has not yet been filed, so detailed terms such as the royalty tiers and escrow mechanics should be reviewed when the exhibit is published.

Aug 25, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 6, 2025)

BeOne Medicines (ONC) reported strong second-quarter 2025 results, with total revenue rising 42% year over year to $1.32 billion ($1.315 billion). Growth was driven by BRUKINSA, whose global revenue increased 49% to $950 million, including U.S. sales of $684 million (up 43%) and European sales of $150 million (up 85%). TEVIMBRA sales grew 22% to $194 million. Gross margin on product sales expanded to 87.4% on a GAAP basis from 85.0%, reflecting a higher mix of BRUKINSA and cost-of-sales productivity gains. The company swung to GAAP operating income of $88 million from a $107 million loss a year earlier, and reported GAAP net income of $94 million, or $0.84 per diluted ADS. Non-GAAP diluted EPS per ADS was $2.25, and free cash flow was $220 million. Operating expenses grew more slowly than revenue. GAAP operating expenses rose 18% to $1.06 billion, with SG&A up 21% on commercial expansion in the U.S. and Europe and R&D up 15%. SG&A fell to 41% of product sales from 48%, which drove most of the operating leverage. The balance sheet strengthened, with cash, cash equivalents and restricted cash of $2.79 billion against debt of $954 million at June 30, 2025. Management raised the low end of its FY2025 total revenue guidance to $5.0–5.3 billion from $4.9–5.3 billion, kept GAAP operating expense guidance at $4.1–4.4 billion, and moved its gross margin outlook to the mid-to-high 80% range. It continues to expect positive GAAP operating income and positive free cash flow for the full year. The main watch items are the sustainability of BRUKINSA's growth against a competitive BTKi class, the pace of pipeline execution (sonrotoclax and BGB-16673 Phase 3 readouts and trial starts are expected in 2H 2025), and the gap between GAAP and non-GAAP results, which is largely driven by share-based compensation. Investors should also note that the filing furnishes the earnings press release under Item 2.02 rather than filing it, and that the guidance is based on forward-looking assumptions that carry significant uncertainty.

Aug 6, 2025 8-K

Shareholder Matters

BeOne Medicines Ltd. 8-K Report, Shareholder Vote Results (May 21, 2025)

BeiGene, Ltd. (ONC) held its Annual Meeting of Shareholders on May 21, 2025, where a significant majority of outstanding shares were represented, indicating strong shareholder engagement. The meeting's primary focus was on the voting of several ordinary resolutions. Key outcomes include the re-election of five directors to their respective classes, demonstrating continued confidence in the company's leadership and governance. Furthermore, shareholders ratified the appointment of Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2025, and authorized the board to fix their compensation. A crucial resolution approved was the General Mandate to Issue Shares, allowing the board to issue up to 20% of the company's total issued shares, which provides flexibility for future financing or strategic initiatives. The General Mandate to Repurchase Shares was also approved, granting the board the authority to repurchase up to 10% of outstanding shares. Additionally, a Connected Person Placing Authorization was approved, allowing for the allocation of shares to Amgen Inc. to maintain its shareholding percentage in future offerings. The compensation of named executive officers was also approved on an advisory basis, and the chairman was granted authority to adjourn the meeting if necessary.

May 21, 2025 8-K

Securities & Listing

BeOne Medicines Ltd. 8-K Report, Unregistered Securities Sale (May 13, 2025)

BeOne Medicines Ltd. (ONC) filed an 8-K on May 13, 2025, detailing the issuance of 133,000,000 ordinary shares to its wholly owned subsidiary, BG NC 2, Ltd. This issuance is a component of the company's proposed re-domiciliation from the Cayman Islands to Switzerland, referred to as the 'Continuation.' These newly issued shares will be held by the subsidiary for the benefit of equity award holders under the Company's 2016 Share Option and Incentive Plan, intended to satisfy outstanding awards post-Continuation. The issuance of these shares is structured to avoid Swiss issuance stamp tax and withholding tax, as they will be fully created and issued before the Continuation. Importantly, these shares are being issued in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act of 1933. The company cautions that the actual outcomes may differ from forward-looking statements due to various risks, including clinical trial results, regulatory actions, and commercial success, as detailed in their SEC filings.

May 13, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (May 7, 2025)

BeiGene, Ltd. (NASDAQ: ONC), which is in the process of renaming itself BeOne Medicines Ltd. and redomiciling to Switzerland, reported first quarter 2025 results on May 7, 2025 that marked its first quarter of GAAP profitability. Total revenue rose 49% year over year to $1.117 billion, driven by BRUKINSA (zanubrutinib) global sales of $792 million, up 62%, with U.S. BRUKINSA sales of $563 million (up 60%) and European sales of $116 million (up 73%). Product revenue was $1.109 billion, and TEVIMBRA contributed $171 million, up 18%. Profitability improved sharply. GAAP income from operations was $11.1 million versus a $261.3 million loss a year earlier, and GAAP net income was $1.3 million ($0.01 per diluted ADS). Non-GAAP adjusted operating income was $139.4 million and adjusted diluted EPS per ADS was $1.22. Gross margin improved to 85.1% on a GAAP basis, and operating cash flow was $44 million, a $353 million swing from the prior-year outflow. Cash, cash equivalents and restricted cash declined to $2.53 billion, and debt fell to $924 million from $1.02 billion at year-end 2024. Management maintained full-year 2025 guidance of $4.9 to $5.3 billion in total revenue and $4.1 to $4.4 billion in GAAP operating expenses, and reiterated targets for a mid-80% gross margin, positive full-year GAAP operating income and positive operating cash flow. For investors, the key takeaways are the transition from losses to GAAP profitability, the continued commercial momentum of BRUKINSA, and the thin GAAP margin in a single quarter, which still depends on sustaining revenue growth against rising R&D and SG&A spending. The quarter also featured an impairment of equity investments of $12.4 million, a favorable Pharmacyclics patent decision, and upcoming catalysts including an Investor R&D Day on June 26, 2025 and several Phase 3 readouts later in 2025.

May 7, 2025 8-K

Shareholder MattersExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Apr 29, 2025)

BeOne Medicines Ltd. (ONC) filed a Current Report on Form 8-K on April 29, 2025, primarily to disclose the cover page of the report itself, formatted in Inline XBRL. This filing does not contain new operational, financial, or material event disclosures beyond the standard reporting requirement for the exhibit. Investors reviewing this specific 8-K filing should note that it serves a procedural purpose related to regulatory compliance and data formatting. There are no substantive business updates, significant financial changes, or material corporate events announced in this particular document. For comprehensive insights into BeOne Medicines' performance and strategic direction, investors should refer to their most recent Form 10-K (Annual Report) and other relevant 8-K filings that contain substantive information.

Apr 29, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Shareholder Vote Results (Apr 28, 2025)

BeOne Medicines Ltd. (ONC) filed a routine Current Report on Form 8-K on April 28, 2025. The primary purpose of this filing was to furnish an exhibit related to the report itself, specifically the cover page formatted in Inline XBRL. This filing does not contain any new material financial information, operational updates, or significant corporate events. Investors should note that this 8-K filing is administrative in nature and does not provide insights into the company's performance, strategic initiatives, or future outlook. Given the limited nature of this disclosure, investors seeking information about BeOne Medicines' current business status, financial health, or strategic direction should refer to their most recent quarterly (10-Q) or annual (10-K) filings, or any other Form 8-K filings that may disclose material events. This particular filing is primarily a compliance requirement for presenting the report's cover page in a machine-readable format.

Apr 28, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Apr 28, 2025)

This Form 8-K furnishes supplemental financial information, not a full earnings release. It was filed alongside BeiGene's 2024 Annual Report on the Shanghai Stock Exchange STAR Market, which PRC rules require to include certain PRC GAAP disclosures. Exhibit 99.1 provides selected U.S. GAAP figures for 2024 and 2023: gross margin by region, R&D expenses by product, and production, sales, and inventory volumes. The filing names the registrant BeiGene, Ltd. rather than BeOne Medicines Ltd. The company renamed itself BeOne Medicines, so the name in the filing reflects the legacy entity name. The Exhibit 99.1 disclosures are not part of the filed 8-K for Section 18 purposes, and the STAR report itself is Chinese-language only and not SEC-filed. The headline data point is revenue growth. Total revenue in the exhibit's gross margin table rose about 55% to $3.81 billion in 2024 from $2.46 billion in 2023. Ex-China revenue grew about 77% to $2.40 billion, while China revenue grew about 28% to $1.41 billion. Ex-China growth therefore drove the mix shift, with ex-China now roughly 63% of revenue versus about 55% a year earlier. Implied total gross margin was essentially flat at roughly 84% on a simple revenue-less-COGS basis. Regional margins compressed modestly: China fell to 62.9% from 68.0%, reflecting pricing and volume-based procurement pressure, while ex-China slipped to 97.1% from 98.0%. R&D spending rose about 10% to $1.95 billion. The increase was concentrated in pipeline assets. BCL-2 inhibitor BGB-11417 (sonrotoclax) spending nearly doubled to $99.9 million, and early-stage programs CDAC (BGB-16673) and CDK4 (BGB-43395) rose sharply from small bases. External R&D collaboration spending nearly doubled to $189.2 million. Zanubrutinib R&D expense declined to $129.2 million from $158.1 million. On the commercial side, the company sold about 5.04 million vials of key products against about 5.01 million produced or purchased in 2024, leaving about 2.64 million vials in inventory at year-end. This filing does not provide forward guidance, so the implications for future periods must be drawn from the underlying annual report.

Apr 28, 2025 8-K

Regulation FDExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Feb 27, 2025)

BeiGene, Ltd. (NASDAQ: ONC), which plans to rename itself BeOne Medicines Ltd., reported strong fourth-quarter and full-year 2024 results in this 8-K, furnished under Item 2.02 with the earnings press release as Exhibit 99.1. Total revenue was $1.13 billion for Q4 (up 78% year over year) and $3.81 billion for FY2024 (up 55%), driven by BRUKINSA, whose global sales reached $828 million in Q4 and $2.6 billion for the year. Profitability improved sharply: the FY2024 GAAP operating loss narrowed to $568 million from $1.21 billion, and non-GAAP adjusted operating income was positive at $45 million for the full year. Gross margin on product sales reached 84.3% on a GAAP basis (85.5% adjusted), and SG&A fell to 48% of product sales from 69%. The balance sheet and cash flow picture is more mixed. FY2024 GAAP net loss was $645 million ($0.47 per share), and cash used in operations was $141 million for the full year, although Q4 operating cash flow was positive at $75 million. Cash, cash equivalents and restricted cash declined to $2.64 billion from $3.19 billion, and debt rose to $1.02 billion. Q4 GAAP results included a $66.5 million income tax expense and $16 million of accelerated depreciation tied to tislelizumab production changes. Management guided FY2025 total revenue to $4.9–5.3 billion, GAAP operating expenses of $4.1–4.4 billion, a mid-80% gross margin, and positive full-year GAAP operating income and operating cash flow. That guidance excludes any new business development activity. For investors, the key questions are whether the BRUKINSA growth trajectory and margin expansion can deliver the first full year of GAAP operating profit in 2025, while funding a large pipeline with a declining cash balance. The company also settled patent litigation with MSN, which allows a generic BRUKINSA in the U.S. no earlier than June 15, 2037, a long runway of exclusivity.

Feb 27, 2025 8-K

BeOne Medicines Ltd. 8-K Report, Regulation FD Disclosure (Jan 13, 2025)

BeOne Medicines Ltd. (ONC) has filed a Current Report on Form 8-K dated January 13, 2025, primarily to disclose exhibits related to the filing. The most significant item provided is Exhibit 104, which is the cover page of the report formatted in Inline XBRL. This indicates a commitment to enhanced data transparency and compliance with modern SEC reporting standards, allowing for easier machine readability and analysis of key report metadata.

Jan 13, 2025 8-K

Material AgreementsFinancial EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Dec 23, 2024)

BeOne Medicines Ltd. (ONC) has filed a Current Report on Form 8-K with the SEC on December 23, 2024. This filing is primarily administrative, related to the submission of exhibits. Specifically, it includes the cover page of the report formatted in Inline XBRL, which is a standard requirement for SEC filings to enhance data accessibility and machine readability.

Dec 23, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Material Agreement (Dec 10, 2024)

BeOne Medicines Ltd. (ONC) announced the entry into a $400 million uncommitted and unsecured credit facility agreement with China Merchants Bank Co., Ltd. This new facility provides flexible access to capital for daily operations and refinancing of existing working capital loans. While uncommitted, meaning the lender is not obligated to provide funds, the agreement offers a significant potential liquidity source. The loans under this facility have a floating interest rate and a term of up to one year, with full repayment required within 18 months of the signing date. The facility includes financial and operating covenants that investors should monitor, such as maintaining specific financial ratios, listing status, and intellectual property protections. This new credit facility replaces an existing $400 million facility set to expire in January 2025, from which ONC currently has $380 million drawn. The company plans to repay $300 million of the existing facility in December 2024, leaving an $80 million balance that will be fully repaid in January 2025 and will also count towards the availability under the new agreement. As of the filing date, no borrowings were outstanding under the new facility, indicating no immediate debt drawdowns associated with it.

Dec 10, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Nov 19, 2024)

On November 19, 2024, BeiGene, Ltd. (NASDAQ: BGNE, now operating as BeOne Medicines and listed as ONC) disclosed under Item 8.01 that its U.S. subsidiaries settled patent litigation with MSN Pharmaceuticals and MSN Laboratories on November 14, 2024. MSN had filed an Abbreviated New Drug Application (ANDA) seeking to market a generic version of BRUKINSA (zanubrutinib) and challenged several Orange Book patents. The settlement grants MSN the right to sell a generic BRUKINSA in the United States no earlier than June 15, 2037, subject to customary acceleration or extension provisions. The composition-of-matter patent, which expires in April 2034, was not challenged in the litigation, so it is not directly affected by the settlement terms as described. The settlement, together with the previously dismissed Sandoz litigation, resolves all patent suits BeiGene brought against companies that filed ANDAs for generic BRUKINSA. For investors, this provides a defined exclusivity runway in the U.S. that extends well beyond the composition-of-matter patent expiry, reducing near-term generic entry risk and supporting long-term revenue visibility for BRUKINSA. The agreement must still be submitted to the U.S. Federal Trade Commission and the Department of Justice, and the parties have filed a joint stipulation to dismiss the MSN suit. The filing contains no quantitative financial data, guidance, or disclosure of settlement payments or royalty terms. Investors should note that the filing is a brief disclosure and that the full Settlement Agreement, along with any regulatory review outcome, will determine the complete economic impact.

Nov 19, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Nov 14, 2024)

BeiGene, Ltd. has announced its intention to change its corporate name to "BeOne Medicines Ltd.", a move that will also coincide with a ticker symbol change to "ONC" on The Nasdaq Global Select Market. This rebranding signifies the company's reinforced commitment to developing innovative medicines aimed at eliminating cancer, emphasizing a collaborative, global approach to patient care. The proposed name change is subject to shareholder approval, which will be sought at a future shareholder meeting. Investors should pay close attention to the upcoming definitive proxy statement, which will provide comprehensive details regarding the name change proposal and related matters. This document will be available for free on the SEC's website and directly from the company. The company also notes that its directors and executive officers may be considered participants in the solicitation of proxies for this vote, and further information on their interests will be disclosed in the proxy statement.

Nov 14, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 12, 2024)

BeiGene, Ltd. (NASDAQ: BGNE; the filing predates its rename to BeOne Medicines) reported third-quarter 2024 total revenue of $1,001.6 million, up 28% from $781.3 million a year earlier. The growth came from product revenue, which rose 67% to $993.4 million, led by BRUKINSA. U.S. BRUKINSA sales were $504 million (up 87%), and European BRUKINSA sales were $97 million (up 217%). Collaboration revenue fell 96% to $8.2 million because the prior-year period included about $183 million of recognized Novartis deferred revenue. The prior-year comparison is therefore distorted, and the underlying product business is the better gauge of momentum. Profitability improved sharply on an adjusted basis. Adjusted operating income was $65.6 million, compared with an adjusted operating loss of $16.3 million a year earlier, and management described it as the second consecutive quarter of positive non-GAAP operating income. GAAP loss from operations narrowed 10% to $120.3 million. GAAP net loss was $121.4 million, or $(1.15) per ADS, compared with net income of $215.4 million in the prior year, which included a $363 million BMS arbitration gain and the Novartis revenue recognition. Operating cash flow turned positive at $188.4 million, versus negative $78.2 million a year earlier. Cash, cash equivalents and restricted cash were $2.71 billion at September 30, 2024, down from $3.19 billion at year-end 2023, while debt rose to $1.05 billion. Investors should watch the cash balance trend and the company's ability to sustain GAAP profitability as launch spending continues.

Nov 12, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Oct 28, 2024)

BeOne Medicines Ltd. (ONC) has filed a Current Report on Form 8-K on October 28, 2024, primarily to disclose the exhibit filed with the report. The filing indicates that the only exhibit is the cover page of the Form 8-K itself, formatted in Inline XBRL. This filing does not contain any substantive financial information, operational updates, or material business events.

Oct 28, 2024 8-K

Leadership ChangesExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Sep 30, 2024)

On September 30, 2024, BeiGene, Ltd. (now BeOne Medicines, the company named in the request) filed a Form 8-K that does not report new financial results. The filing responds to a July 25, 2024 SEC Division of Corporation Finance comment letter asking the company to restore China-related legal and operational risk factor language to the wording in its 2022 Form 10-K. The company re-filed its full Item 1A risk factors as Exhibit 99.1, with asterisks marking risk factors that are newly added or materially updated since the 2023 Form 10-K. The most investor-relevant content is in the updated risk factors. The company highlights a rising accumulated deficit of $8.4 billion as of August 31, 2024, up from $8.0 billion at year-end 2023. It also reports operating cash outflows of $404.2 million in the first six months of 2024, versus $857.7 million in the same period of 2023, and cash and equivalents of $2.6 billion. It states that it believes current cash is sufficient for at least 12 months, but flags that its debt is mostly short-term, carries cross-default provisions, and that it may need additional financing. New or updated disclosures also cover patent litigation (Sandoz and MSN ANDA suits filed March 2024, a Pharmacyclics suit against BRUKINSA, and an AbbVie trade secret lawsuit filed September 2024), Chinese human genetic resources (HGR) rules, PRC government oversight of offerings and operations, and pricing pressure from China's volume-based procurement and NRDL reimbursement. For investors, the filing is primarily a disclosure-compliance event rather than a fundamental change in the business. Its main value is as a more detailed and current statement of China-specific, regulatory, litigation and liquidity risks. Investors should read it alongside the company's most recent Form 10-Q, which the restated risk factors expressly incorporate.

Sep 30, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Executive Changes (Sep 26, 2024)

This Form 8-K reports a board governance change rather than financial results. The registrant, identified in the filing as BeiGene, Ltd. (the company now operating as BeOne Medicines), increased its board from 11 to 12 members and appointed Shalini Sharp as a Class III director, effective September 27, 2024. She also joined the Audit Committee, which is a meaningful addition given the company's stated focus on reaching profitability. The filing contains no revenue, earnings, guidance, or balance sheet data, so the near-term financial impact is limited to governance and oversight. Ms. Sharp brings substantial pharmaceutical finance experience. She previously served as CFO of Ultragenyx Pharmaceuticals and as CFO of Agenus, and she currently sits on the boards of Neurocrine Biosciences and Organon & Co. Her background in investment banking and McKinsey adds to her financial credentials. The company's press release frames her appointment around entering new markets, advancing the oncology pipeline, and reaching profitability, but these are management statements rather than quantified commitments. Compensation for Ms. Sharp is modest and follows the company's standard non-employee director policy. She receives equity awards valued at US$400,000 (pro-rated in her first year), $65,000 in annual director cash compensation, and $17,500 in annual Audit Committee cash compensation. Her equity awards are options and RSUs that vest on the earlier of the first anniversary of grant or the next annual meeting, with accelerated vesting on death, disability, or certain change-of-control events. The filing reports no related-party transactions and no arrangements under which she was selected.

Sep 26, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 29, 2024)

On August 29, 2024, BeiGene, Ltd. (ONC, now BeOne Medicines) filed this Form 8-K to furnish supplemental financial information tied to its 2024 Interim Report for the six months ended June 30, 2024. That report was filed with the Shanghai Stock Exchange's STAR Market under PRC rules. The 8-K contains no new headline U.S. results such as revenue, net loss, or EPS. Its substance is a breakdown of research and development (R&D) expenses by key product and project, presented under U.S. GAAP, along with a summary of the differences between PRC GAAP and U.S. GAAP. The Chinese-language STAR report is not part of this filing and is not deemed filed with the SEC. The R&D allocation shows total R&D expense of $915.1 million for the first half of 2024, up about 10% from $831.3 million a year earlier. External R&D rose about 17% to $330.1 million, including $82.5 million in R&D collaboration projects (up from $23.3 million). Internal R&D grew about 6% to $585.0 million. The mix shifted toward newer programs. Bcl-2 (BGB-11417) expense more than doubled to $38.6 million, and CDAC (BGB-16673) rose to $5.7 million from $1.1 million. Expense for the commercial anchors fell: zanubrutinib dropped about 22% to $62.9 million and tislelizumab about 27% to $34.5 million. Pamiparib, ociperlimab, and OX40 also declined. For investors, the main takeaways are the continued growth of total R&D spend, the rising weight of collaboration and early-stage programs, and the lower R&D investment behind the two established products. Because the document is a regulatory supplement rather than an earnings release, it is best read alongside the company's U.S. quarterly filings for revenue, profitability, and pipeline milestones.

Aug 29, 2024 8-K

Leadership ChangesRegulation FDExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Aug 7, 2024)

This 8-K from BeiGene, Ltd. (later renamed BeOne Medicines; the filing itself uses the BeiGene name) furnishes second-quarter 2024 results and corporate updates. Total revenue rose 56% year over year to $929 million, driven by BRUKINSA, whose global revenue reached $637 million (up 107%). Product revenue grew 66% to $921 million, and gross margin on product sales improved to 85% from 83%. The most significant development for investors is the first quarter of positive non-GAAP operating income, at $48 million versus a $193 million loss a year earlier. GAAP operating loss narrowed 66% to $107 million, and GAAP net loss fell to $120 million, or $(1.15) per ADS, from $381 million. The quarter's cash burn also improved sharply. Cash used in operations was $96 million, compared with $294 million a year earlier, but cash, cash equivalents and restricted cash still declined to $2.62 billion from $3.19 billion at year-end 2023, and debt increased to $1.04 billion. The company also flagged a regulatory setback: FDA deferred its decision on tislelizumab in first-line esophageal squamous cell carcinoma because of delays in scheduling clinical site inspections. Management also announced a proposal to redomicile from the Cayman Islands to Switzerland, which is subject to shareholder approval, and opened a $800 million flagship U.S. biologics manufacturing facility in New Jersey. The pipeline is broad, with more than 15 solid tumor molecules in development, and the hematology franchise is central to the growth story. Sonrotoclax (BCL2 inhibitor) has completed enrollment in a global Phase 2 trial in relapsed/refractory mantle cell lymphoma, and the BTK degrader BGB-16673 is advancing toward Phase 3 entry expected in late 2024 or early 2025. Investors should weigh the strong top-line momentum and progress toward operating profitability against continued heavy R&D and SG&A spending, the still-large cash balance decline, and the tislelizumab regulatory delay.

Aug 7, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jul 18, 2024)

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235) announced on July 18, 2024, that Aaron Rosenberg will become Chief Financial Officer and principal financial officer effective July 22, 2024. Rosenberg most recently served as Senior Vice President and Corporate Treasurer at Merck & Co. (July 2021 to July 2024), with more than 20 years at Merck in finance and strategy roles. The company's management described his appointment as coming at an "inflection point" in its growth. The filing does not disclose any change to financial guidance or operating results. The transition follows the July 17, 2024 resignation of current CFO Julia Wang, effective July 19, 2024. Wang will serve as Senior Advisor through August 31, 2024. Her separation package totals about US$1.49 million in cash (18 months of base salary plus 18 months of target bonus and dental premiums), along with 18 months of accelerated vesting on pre-2024 RSUs and share options and an extended option exercise window. The company states that her departure did not result from any disagreement with the board, management, or company operations, policies, or practices. Rosenberg's compensation is substantial. He receives a US$620,000 base salary, a 60% target bonus, and an initial equity grant valued at US$5 million, split evenly among RSUs, share options, and PSUs, subject to board or compensation committee approval. His severance terms include 12 months of base salary and COBRA coverage, with enhanced acceleration after a change in control. Investors may view the appointment as a continuity-oriented hire from a major pharma company, while the executive transition itself is a routine but notable event that merits monitoring during the handover period.

Jul 18, 2024 8-K

Leadership ChangesShareholder MattersExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jun 5, 2024)

BeiGene, Ltd. (ONC) filed an 8-K on June 5, 2024, detailing the outcomes of its 2024 Annual General Meeting of Shareholders. The most significant investor-focused updates involve the shareholder approval of amendments to key equity incentive plans. Specifically, the Third Amended and Restated 2016 Share Option and Incentive Plan and the Fourth Amended and Restated 2018 Employee Share Purchase Plan were approved. These amendments, driven by changes in Hong Kong Listing Rules, include substantial increases in the number of shares available for issuance under these plans. The former plan now has an additional 92,820,000 shares available, while the latter has an additional 5,070,000 shares available. Furthermore, the meeting saw the re-election of several Class II directors, including Dr. Olivier Brandicourt, Mr. Donald W. Glazer, Mr. Michael Goller, and Dr. Corazon (Corsee) D. Sanders, all approved by significant margins. The company also received shareholder approval for a general mandate to issue up to 20% of its outstanding shares and a mandate to repurchase up to 10% of its outstanding shares, providing flexibility for capital management. Additionally, significant grants of Restricted Share Units (RSUs) and Performance Share Units (PSUs) to named executive officers, including CEO John V. Oyler and Dr. Xiaodong Wang, were approved, along with advisory votes on executive compensation and the frequency of future say-on-pay votes, which will be held annually.

Jun 5, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (May 8, 2024)

BeiGene, Ltd. (NASDAQ: BGNE), which has since been renamed BeOne Medicines, reported first quarter 2024 total revenue of $752 million, up 68% year over year. Product revenue rose 82% to $747 million, led by BRUKINSA, with U.S. sales of $351 million (up 153%) and European sales of $67 million (up 243%). Gross margin on product revenue improved to 83% from 80%, and SG&A fell to 57% of product sales from 80%. Collaboration revenue dropped 87% to $5 million, reflecting the prior-year period's higher collaboration income. GAAP operating loss narrowed 30% to $261 million, and adjusted operating loss narrowed 47% to $147 million, which management attributes to operating leverage from revenue growth and expense discipline. GAAP net loss improved to $251 million from $348 million, or $(0.19) per share and $(2.41) per ADS. Operating cash burn fell sharply to $309 million from $564 million. Cash, cash equivalents, restricted cash and short-term investments declined to $2.81 billion from $3.19 billion at year-end 2023, while debt rose to about $1.03 billion from $886 million, so liquidity and the path to sustained profitability remain key watch items. Pipeline and regulatory news was mixed. Tislelizumab sales grew 26% to $145 million, and the company received FDA approval for second-line esophageal cancer, but management warned that the July 2024 PDUFA date for first-line ESCC may be deferred due to possible delays in clinical site inspection scheduling. The company also reported FDA fast track designation for sonrotoclax in relapsed or refractory mantle cell lymphoma and a USPTO decision to institute post-grant review of a Pharmacyclics patent. Note that the 8-K portions furnished under Item 2.02 are not deemed filed for Exchange Act Section 18 purposes.

May 8, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Apr 26, 2024)

This 8-K, filed April 26, 2024 by BeiGene, Ltd. (now BeOne Medicines, ticker ONC), is a supplemental disclosure rather than an earnings release. It furnishes Exhibit 99.1, which restates selected 2023 figures under U.S. GAAP that BeiGene was required to publish under PRC rules alongside its STAR Market annual report. The exhibit covers gross margin by region, R&D spending by product, and production and inventory volumes. The filing is not subject to Section 18 liability and does not include a full earnings release or guidance. The figures show strong 2023 top-line growth. Total revenue rose about 74% to $2.46 billion from $1.42 billion, driven mainly by ex-China revenue, which more than doubled to $1.36 billion. China revenue grew about 31% to $1.10 billion. Blended gross margin, calculated from the disclosed revenue and cost of goods sold, expanded to roughly 84.5% from about 79.8%. The mix shift toward high-margin ex-China sales (98% gross margin) is the main driver, while China gross margin improved modestly to 68.0%. R&D spending increased about 8% to $1.78 billion. Internal R&D grew about 12%, while external R&D was nearly flat, with collaboration spending down about 40%. Within the pipeline, zanubrutinib spending rose about 25% and the Bcl-2 program (BGB-11417, now sonrotoclax) more than doubled. Ociperlimab spending fell about 27%. The disclosure is backward-looking, so investors should treat it as historical context. Its main value is in confirming the revenue and margin trajectory and reconciling PRC and U.S. reporting.

Apr 26, 2024 8-K

Leadership ChangesOther EventsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Apr 23, 2024)

BeiGene, Ltd. (NASDAQ: BGNE; the user referred to the issuer as BeOne Medicines Ltd. (ONC), but the filing itself names BeiGene) disclosed in a voluntary Item 8.01 Form 8-K that the European Commission approved tislelizumab for non-small cell lung cancer (NSCLC) across three indications: first-line squamous NSCLC, first-line non-squamous NSCLC with PD-L1 expression on at least 50% of tumor cells, and second-line or later monotherapy. The approval is the drug's second in the EU, following the earlier approval for esophageal squamous cell carcinoma (ESCC). The NSCLC indications are branded TIZVENI, and BeiGene plans to combine them with the ESCC indication under the TEVIMBRA brand, with launches in the first EU countries later in 2024. The approval rests on three Phase 3 RATIONALE trials totaling 1,499 patients. RATIONALE 303 showed a statistically significant overall survival benefit versus docetaxel in previously platinum-treated patients (HR 0.66; P<0.0001). RATIONALE 304 and RATIONALE 307 showed statistically significant progression-free survival improvements in first-line non-squamous and squamous NSCLC, respectively. The company also noted that a U.S. FDA approval for second-line ESCC came only weeks earlier, and that TEVIMBRA is under review by the EMA and FDA for additional first-line ESCC and gastric/gastroesophageal junction cancer indications. The filing is a regulatory-milestone announcement. It does not disclose revenue guidance, launch-related financial projections, or any quantified financial impact. For investors, the key takeaways are the expansion of the tislelizumab label across lung cancer settings in a major market, the incremental commercial opportunity this creates ahead of the 2024 EU launch, and the continued regulatory progress across multiple tumor types, while the actual financial contribution will depend on uptake, pricing and reimbursement, and competition in NSCLC.

Apr 23, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Executive Changes (Mar 20, 2024)

BeiGene, Ltd. (ONC) announced a key change in its accounting leadership through an 8-K filing on March 20, 2024. The company has appointed Titus Ball as its new Principal Accounting Officer, effective March 19, 2024. Mr. Ball, who joined BeiGene in August 2023 as Vice President and Chief Accounting Officer, brings a strong background in accounting and finance from his previous roles at KPMG and Carlisle Companies Inc., including a tenure as VP & Chief Accounting Officer at Carlisle. This transition sees the responsibilities shift from CFO Julia Wang, who will continue in her roles as Chief Financial Officer and Principal Financial Officer. Additionally, the company's Board of Directors approved amendments to its Independent Director Compensation Policy. Effective April 1, 2024, the annual cash retainers for the chairperson and members of the Nominating and Corporate Governance Committee will see modest increases. Specifically, the chairperson's retainer will rise by $2,000 to $20,000 annually, and members' retainers will increase by $1,000 to $10,000 annually. These changes aim to further align compensation with the responsibilities of these key oversight roles, with no alterations to the equity award components.

Mar 20, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Mar 15, 2024)

BeiGene, Ltd. (the filing names the company as BeiGene; the request refers to it as BeOne Medicines Ltd. (ONC), which reflects a later corporate name change) disclosed in this Form 8-K, filed March 15, 2024, that the U.S. FDA approved TEVIMBRA (tislelizumab-jsgr) as monotherapy for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. U.S. commercial availability is expected in the second half of 2024. The filing contains no financial statements, revenue figures, or guidance, so its investment significance rests on the regulatory and commercial milestone it reports. The approval is supported by the global Phase 3 RATIONALE 302 trial (512 patients). In the intention-to-treat population, median overall survival was 8.6 months with TEVIMBRA versus 6.3 months with chemotherapy (HR 0.70; 95% CI 0.57 to 0.85; p=0.0001). The company describes the safety profile as favorable versus chemotherapy. The label carries a boxed-style set of immune-mediated risks, including pneumonitis (3.8% incidence, 0.2% fatal), colitis, hepatitis, endocrinopathies, and nephritis, and permanent discontinuation due to adverse reactions occurred in 19% of patients. These risks are relevant to uptake and label-driven commercial positioning. The approval is the company's second U.S. approved medicine and its first from its immuno-oncology program. Further upside depends on pending FDA reviews: a first-line ESCC BLA with a July 2024 target action date and a first-line gastric/GEJ adenocarcinoma BLA with a December 2024 target action date. Investors should weigh these catalysts against a competitive PD-1 landscape and the company's continued path to profitability, as noted in the forward-looking statement risk factors.

Mar 15, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Mar 8, 2024)

BeOne Medicines Ltd. (ONC) filed a Current Report on Form 8-K on March 8, 2024, primarily to disclose exhibits filed with the report. The most significant exhibit is the cover page of the Current Report itself, formatted in Inline XBRL. This filing does not appear to contain any new material financial information, operational updates, or significant corporate events that would typically warrant a detailed analysis for investors beyond the standard reporting requirement of including XBRL formatted documents.

Mar 8, 2024 8-K

Leadership ChangesExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Financial Results (Feb 26, 2024)

BeiGene, Ltd. (now BeOne Medicines, ticker ONC) reported fourth-quarter and full-year 2023 results on February 26, 2024. Total revenue reached $634.4 million in Q4 and $2.46 billion for the full year, up 67% and 74% year over year. Growth was driven by BRUKINSA, whose global sales were $413.0 million in Q4 and $1.3 billion for the year, up 135% and 129%. U.S. revenue more than doubled to $1.1 billion for 2023, and management expects U.S. BRUKINSA sales to keep growing in 2024. Profitability improved substantially. Gross margin on product sales was 82.7% for the year, versus 77.2% in 2022. GAAP operating loss narrowed to $1.21 billion from $1.79 billion, and adjusted operating loss narrowed to $752 million from $1.42 billion. The GAAP net loss of $881.7 million ($0.65 per share) was flattered by a $362.9 million non-operating gain from the BMS arbitration settlement, so the underlying operating loss is the better measure of run-rate performance. Operating cash burn was still about $1.2 billion for 2023, and cash, equivalents, restricted cash and short-term investments fell to $3.19 billion from $4.54 billion, while debt rose to $886 million from $538 million. The filing also lays out 2024 catalysts, including a targeted March 2024 FDA decision on BRUKINSA with obinutuzumab in relapsed/refractory follicular lymphoma, several tislelizumab approval decisions across ESCC and NSCLC, and the expected July 2024 operational date for the Princeton, New Jersey biologics facility. Note that Item 2.02 results are furnished, while the Item 8.01 pipeline and milestone content is filed. These forward-looking milestones are management expectations and carry regulatory and execution risk.

Feb 26, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Executive Changes (Jan 23, 2024)

BeiGene, Ltd. (NASDAQ: BGNE; now renamed BeOne Medicines Ltd., ticker ONC) disclosed a board change in this 8-K. Thomas Malley resigned from the Board on January 22, 2024, and from the Audit Committee and Scientific Advisory Committee. He had served since 2016, and the company states his departure was not due to any disagreement with its operations, policies, or practices. The Board filled the vacancy the next day, January 23, 2024, by appointing Olivier Brandicourt, M.D., a former CEO of Sanofi S.A. and Bayer HealthCare AG. Dr. Brandicourt joins the Audit Committee, which signals that the Board values his global commercial and senior management experience as the company expands internationally. For investors, this is a routine governance event with no direct financial impact disclosed in the filing. The compensation package follows the company's existing independent director policy: share options valued at US$400,000 (pro-rated in year one), US$65,000 in annual director cash retainer, and US$17,500 for Audit Committee service. The options carry an exercise price set at the greater of the grant-date fair market value and the five-day average, and they vest on the earlier of the first anniversary or the next annual meeting. Dr. Brandicourt's appointment is a Class II director seat, which runs until the June 2024 Annual General Meeting of Shareholders, where shareholders will have the opportunity to re-elect him. The filing also discloses no related-party transactions under Item 404(a) and no arrangements or understandings tied to his election. A notable point for governance-focused investors is that Dr. Brandicourt currently serves on several external boards, including Alnylam Pharmaceuticals, BenevolentAI, and Dewpoint Therapeutics, and chairs AvenCell Therapeutics. He is also a Senior Advisor at Blackstone Life Sciences. Investors may want to monitor potential time-commitment or conflict considerations as his roles develop.

Jan 23, 2024 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Dec 8, 2023)

BeiGene, Ltd. (ONC) announced on December 8, 2023, the execution of a 2024 Consulting Agreement with Dr. Xiaodong Wang, a key figure in the company as co-founder, director, and Chairman of the Scientific Advisory Board. This agreement renews his existing consulting arrangement, which is set to expire at the end of 2023, on substantially similar terms. Dr. Wang will continue to offer scientific and strategic advisory services. The agreement provides for an annual fixed consulting fee of $100,000, with the possibility of additional compensation at the company's discretion, subject to stock exchange rules. The new agreement is effective from January 1, 2024, and will run until December 31, 2026. This renewal underscores the company's continued reliance on Dr. Wang's expertise in guiding its scientific direction.

Dec 8, 2023 8-K

BeOne Medicines Ltd. 8-K Report, Financial Results (Nov 9, 2023)

BeiGene, Ltd. (NASDAQ: BGNE; now BeOne Medicines, ticker ONC) reported third-quarter 2023 results that showed strong top-line growth and a sharp improvement in operating performance. Total revenue was $781.3 million, up 101.6% year over year, and product revenue was $595.3 million, up 70.3%. Growth was led by BRUKINSA, with global sales of $357.7 million (up 130%), including $270.1 million in the U.S. and $47.4 million in China. Gross margin on product revenue expanded to 83.8% from 78.1%. Part of the revenue jump reflects one-time recognition of remaining deferred revenue from the Novartis collaborations, and net income of $215.4 million was boosted by a $362.9 million non-operating gain from the BMS arbitration settlement. Operating loss narrowed to $134.0 million from $438.4 million, and cash used in operations fell to $78.2 million from $561.9 million. The quarter's core signal for investors is operating leverage. Operating expenses (excluding cost of sales) rose 9.3% to $819.0 million, well below product revenue growth, and management expects that gap to persist. Balance-sheet cash, cash equivalents, restricted cash and short-term investments declined to $3.2 billion from $4.5 billion at year-end 2022, so the company still needs to manage its cash burn and its capital investments, including new manufacturing facilities in the U.S. and China. Pipeline catalysts include an expected FDA approval of BRUKINSA's progression-free survival label in R/R CLL/SLL in Q4 2023, additional ALPINE data at ASH in December 2023, and a tislelizumab first-line ESCC PDUFA date in July 2024. The company also regained global rights to TEVIMBRA (tislelizumab), received its first EU approval for that drug, and terminated its Zymeworks ZW49 license in Asia-Pacific. The filing is an 8-K furnishing the earnings press release under Item 2.02, which is not deemed 'filed' for Section 18 liability purposes. Investors should read the figures together with the Form 10-Q, since the headline net income and EPS are inflated by the one-time arbitration gain and the recognition of deferred revenue.

Nov 9, 2023 8-K

BeOne Medicines Ltd. 8-K Report, Corporate Update (Oct 20, 2023)

BeiGene, Ltd. (filed as BGNE on Nasdaq; the company is now known as BeOne Medicines, ticker ONC) reported that the UK's National Institute for Health and Care Excellence (NICE) issued a final draft guidance recommending BRUKINSA (zanubrutinib) for three adult CLL populations: untreated high-risk CLL (17p deletion or TP53 mutation), untreated CLL where FCR or BR chemo-immunotherapy is unsuitable, and relapsed or refractory CLL. NICE found zanubrutinib had lower incremental costs and more incremental quality-adjusted life years than other BTK inhibitors, and considered it a cost-effective use of NHS resources. The filing describes this as a regulatory and market-access milestone for England and Wales. It is furnished under Item 8.01 (Other Events), not Item 2.02, and includes no financial results, guidance, or quantified revenue impact. For investors, the event is incremental. A final draft guidance is a recommendation for routine NHS commissioning, not a binding funding decision. It makes BRUKINSA the third BTK inhibitor for CLL recommended by NICE for routine commissioning, which supports UK reimbursement and access for a growing indication. The press release also notes a prior NICE approval in July 2022 for Waldenstrom's macroglobulinemia and a Scottish Medicines Consortium approval on October 9, 2023 for chemo-immunotherapy-unsuitable CLL. Market size is modest: roughly 3,800 people are diagnosed with CLL in the UK each year. The filing is a press-release furnishing with standard forward-looking statement cautions. It does not indicate a material financial effect, and the UK is a relatively new market for the company. Investors should treat this as a supportive commercial-access development rather than a material change to the company's financial position.

Oct 20, 2023 8-K

Material AgreementsExhibits & Filings

BeOne Medicines Ltd. 8-K Report, Corporate Update (Sep 21, 2023)

This Form 8-K, filed September 21, 2023, reports two regulatory developments for TEVIMBRA (tislelizumab) in esophageal squamous cell carcinoma (ESCC), announced in a September 19, 2023 press release (Exhibit 99.1). The European Commission approved TEVIMBRA as monotherapy for adults with unresectable, locally advanced or metastatic ESCC after prior platinum-based chemotherapy, based on the Phase 3 RATIONALE 302 study. Separately, the U.S. FDA accepted a Biologics License Application for TEVIMBRA as a first-line treatment for the same patient population, with a PDUFA target action date in the second half of 2024. The FDA also granted Orphan Drug Designation for previously untreated advanced or metastatic ESCC. The filing is a regulatory update and contains no financial results, guidance, revenue figures, or quantified commercial impact. The company said it recently regained full global rights to tislelizumab and plans to use this control to accelerate development and commercialization. Investors should view these approvals and filings as incremental progress toward expanding the drug's addressable market, with the material U.S. first-line decision still pending. Note that the filing was issued by BeiGene, Ltd. (NASDAQ: BGNE), the company's name at the time; the ticker ONC corresponds to the later BeOne Medicines identity. Key risks include the pending FDA review outcome and timing, the reliance on the RATIONALE 302 and RATIONALE 306 trial data, and the commercial execution required to compete in a disease with limited treatment options. The press release's forward-looking statements caution that actual results may differ materially.

Sep 21, 2023 8-K

BeOne Medicines Ltd. 8-K Report, Agreement Terminated (Sep 19, 2023)

BeOne Medicines Ltd. (ONC) filed a Current Report on Form 8-K on September 19, 2023, primarily to disclose exhibit information. The filing indicates the inclusion of the cover page of the report itself, formatted in Inline XBRL. This is a standard procedural filing and does not contain new operational, financial, or strategic business updates for investors. Investors should look to other filings or press releases for material information regarding the company's performance, clinical trials, or future outlook.

Sep 19, 2023 8-K